Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab.
Sravya M BhatiaRobert D StreileinRussell P HallPublished in: PloS one (2020)
Disease activity significantly decreased in patients from T1 to T2 (p < .0001). A significant difference was seen in IgG anti-DSG1 (p < .0001) and anti-DSG3 (p = .0049) levels when T1 was compared to T2 in both treatment groups. A significant increase was found between pemphigus patients and normal subjects with nAChR (p < .0001) at T1 but not with m3AChR, TPO or VZV Abs. No significant difference was seen between T1 and T2 values in patients with pemphigus for the non-desmoglein Abs TPO (p = .7559), M3AChR (p = .9003), nAChR (p = .5143) or VZV (p = .2454). These findings demonstrate that although an increase in IgG anti-nAChR autoAbs was found in PV and PF subjects, these Abs did not decrease with treatment. No other non-DSG Abs were increased or significantly changed over time in patients with pemphigus. This suggests that anti -AChR and -TPO Abs may not play a direct role in the pathogenesis of most patients with pemphigus, but does not rule out a role for non-DSG auto antibodies in distinct subsets of pemphigus patient.
Keyphrases
- end stage renal disease
- disease activity
- newly diagnosed
- systemic lupus erythematosus
- ejection fraction
- chronic kidney disease
- rheumatoid arthritis
- peritoneal dialysis
- prognostic factors
- ankylosing spondylitis
- rheumatoid arthritis patients
- diffuse large b cell lymphoma
- peripheral blood
- minimally invasive
- juvenile idiopathic arthritis